featured
Maintenance Risankizumab Therapy Sustains Induction Response in Patients With Crohn's Disease
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Journal of Crohn's & Colitis
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial
J Crohns Colitis 2024 Mar 01;18(3)416-423, M Ferrante, PM Irving, MT Abreu, J Axler, X Gao, Q Cao, T Fujii, A Rausch, J Torres, E Neimark, A Song, K Wallace, K Kligys, S Berg, X Liao, Q Zhou, J Kalabic, B Feagan, R PanaccioneFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.